DC:GEN Genmab A/S

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL, follicular lymphoma, and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, amyloidosis, and solid tumors; Tisotumab vedotin, HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; HuMax-TAC-ADC (ADCT-301) to treat lymphoma and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for metastatic solid tumors; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 for MM; and AMG 714 for the treatment of celiac disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.This company has ADRs that trade in the U.S. as the symbol GMAB.

1,958.50 EUR
As of 06/10/2020


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Other
Index country:  Denmark
Country of incorporation:  Denmark
IPO date:  10/19/2000
Stock exchange:    Omx Nordic Exchange Copen
Exchange country:   Denmark
Market cap:   79,108,710,400 EUR
Current dividend yield:   0.00%
Sedol:      4595739

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy